Document ID: chunk:federal_register_of_legislation:F2024L01325:front:0:p3
Version: federal_register_of_legislation:F2024L01325
Segment Type: other
Provision Reference: 
Character Range: 6623–9772

ceased, within 20 years of cessation;
 1.           having received a cumulative equivalent dose of at least 0.01 sievert of ionising radiation to the bone marrow at least 1 year before clinical onset;
Note: cumulative equivalent dose is defined in the Schedule 1 – Dictionary
 1.           undergoing ablative treatment with radioactive iodine for thyroid cancer between 6 months and 3 years before clinical onset.
 2.           undergoing treatment with radioactive phosphorus for polycythaemia vera before clinical onset, where the first exposure occurred at least one year before clinical onset.
 3.           being exposed to benzene:
         1.           for a cumulative total of at least 1,250 hours within a continuous period of ten years before clinical onset; and
         2.           where the first exposure in that period occurred at least five years before clinical onset;
Note: being exposed to benzene is defined in the Schedule 1 - Dictionary.
 1.           receiving greater than 5 ppm-years of cumulative exposure to benzene before clinical onset, where the first exposure occurred at least 5 years before clinical onset;
Note: ppm-years is defined in the Schedule 1 - Dictionary.
 1.           having acquired immunodeficiency syndrome before clinical onset;
 2.           being obese for at least 5 years within the 20 years before clinical onset;
Note: being obese is defined in the Schedule 1 - Dictionary.
 1.       having one of the following autoimmune diseases before clinical onset;
         1.           pernicious anaemia;
         2.           polymyalgia rheumatica;
         3.           rheumatoid arthritis;
         4.           systemic lupus erythematosus; or
         5.           Behcet's disease;
 2.       completing a course of therapy for malignant neoplasm before clinical onset, where the first exposure occurred at least 6 months before  clinical onset, and where that therapy has ceased, clinical onset occurred within 20 years of cessation;
 3.       inability to obtain appropriate clinical management for myelodysplastic neoplasm (syndrome) before clinical worsening.
 1.            Relationship to service
         1.           The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.
         2.           The factor set out in subsection 9(12) applies only to material contribution to, or aggravation of, myelodysplastic neoplasm (syndrome) where the person's myelodysplastic neoplasm (syndrome) was suffered or contracted before or during (but did not arise out of) the person's relevant service.
 2.            Factors referring to an injury or disease covered by another Statement of Principles
In this Statement of Principles:
 1.           if a factor referred to in section 9 applies in relation to a person; and
 2.           that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;
then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to